[Phenotypic heterogeneity and phenotype-genotype correlations in dystrophinopathies: Contribution of genetic and clinical databases].

[1]  J. Pépin,et al.  Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[2]  J. Cabane,et al.  Dystrophie musculaire de Becker à révélation tardive. À propos d’un nouveau patient et de 12 observations de la littérature , 2011 .

[3]  G. Lanfranchi,et al.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy , 2010, Neurology.

[4]  A. Girardet,et al.  Banques de données de mutations : enjeux et perspectives pour les maladies génétiques orphelines , 2010 .

[5]  E. Fombonne,et al.  Diagnostic and Assessment Issues in Autism Surveillance and Prevalence , 2010 .

[6]  F. Rivier,et al.  Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. , 2009, Human molecular genetics.

[7]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet. Neurology.

[8]  N. Goemans,et al.  T.O.4 A phase I/IIa study on antisense compound PRO051 in patients with Duchenne muscular dystrophy , 2009, Neuromuscular Disorders.

[9]  J. Vles,et al.  Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive Disorder , 2008, Journal of child neurology.

[10]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[11]  Mattias Ekman,et al.  Estimating the Cost of Epilepsy in Europe: A Review with Economic Modeling , 2007, Epilepsia.

[12]  L. Virta,et al.  Prevalence of intellectual disability: a comprehensive study based on national registers. , 2007, Journal of intellectual disability research : JIDR.

[13]  L. Rohde,et al.  Epidemiology of attention-deficit/hyperactivity disorder across the lifespan , 2007, Current opinion in psychiatry.

[14]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[15]  C. Tsao,et al.  Coexisting Muscular Dystrophies and Epilepsy in Children , 2006, Journal of child neurology.

[16]  K. Greenwood,et al.  Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. , 2001 .

[17]  A. Toutain,et al.  Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy? , 1998, American journal of medical genetics.

[18]  R G H Cotton,et al.  The HUGO Mutation Database Initiative , 1998, The Pharmacogenomics Journal.

[19]  S. di Somma,et al.  Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. , 1996, JAMA.

[20]  K. North,et al.  Cognitive dysfunction as the major presenting feature of Becker's muscular dystrophy , 1996, Neurology.

[21]  A. Emery.  Population frequencies of inherited neuromuscular diseases—A world survey , 1991, Neuromuscular Disorders.

[22]  E. Hoffman,et al.  Quadriceps myopathy: Forme fruste of Becker muscular dystrophy , 1990, Annals of neurology.

[23]  J. Miller,et al.  Duchenne muscular dystrophy , 1989, Neurology.

[24]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[25]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[26]  J. Miller,et al.  Clinical investigation in duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history , 1983, Muscle & nerve.

[27]  V. Dubowitz,et al.  Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy , 1982, Muscle & nerve.

[28]  Y. Rideau,et al.  Respiratory function in the muscular dystrophies , 1981, Muscle & nerve.

[29]  F. Muntoni,et al.  Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. , 1998, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[30]  J. Bach,et al.  Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. , 1997, Archives of physical medicine and rehabilitation.

[31]  F. Muntoni,et al.  Epilepsy in Duchenne and Becker muscular dystrophies. , 1997, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[32]  R. Bies.  X-linked dilated cardiomyopathy. , 1994, The New England journal of medicine.